Literature DB >> 26475632

Clinicopathological and molecular features of sessile serrated adenomas with dysplasia or carcinoma.

Mark Bettington1,2,3, Neal Walker1,2, Christophe Rosty1,2, Ian Brown2, Andrew Clouston1,2, Diane McKeone3, Sally-Ann Pearson3, Barbara Leggett1,3,4, Vicki Whitehall1,3,5.   

Abstract

OBJECTIVE: Sessile serrated adenomas (SSAs) are the precursors of at least 15% of colorectal carcinomas, but their biology is incompletely understood. We performed a clinicopathological and molecular analysis of a large number of the rarely observed SSAs with dysplasia/carcinoma to better define their features and the pathways by which they progress to carcinoma.
DESIGN: A cross-sectional analysis of 137 SSAs containing regions of dysplasia/carcinoma prospectively collected at a community GI pathology practice was conducted. Samples were examined for BRAF and KRAS mutations, the CpG island methylator phenotype (CIMP) and immunostained for MLH1, p53, p16, β-catenin and 0-6-methylguanine DNA methyltransferase (MGMT).
RESULTS: The median polyp size was 9 mm and 86.5% were proximal. Most were BRAF mutated (92.7%) and 94.0% showed CIMP. Mismatch repair deficiency, evidenced by loss of MLH1 (74.5%) is associated with older age (76.7 versus 71.0; p<0.0029), female gender (70% versus 36%; p<0.0008), proximal location (91% versus 72%; p<0.02), CIMP (98% versus 80%; p<0.02) and lack of aberrant p53 (7% versus 34%; p<0.001) when compared with the mismatch repair-proficient cases. Loss of p16 (43.1%) and gain of nuclear β-catenin (55.5%) were common in areas of dysplasia/cancer, irrespective of mismatch repair status.
CONCLUSIONS: SSAs containing dysplasia/carcinoma are predominantly small (<10 mm) and proximal. The mismatch repair status separates these lesions into distinct clinicopathological subgroups, although WNT activation and p16 silencing are common to both. Cases with dysplasia occur at a similar age to cases with carcinoma. This, together with the rarity of these 'caught in the act' lesions, suggests a rapid transition to malignancy following a long dwell time as an SSA without dysplasia. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Entities:  

Keywords:  COLON CARCINOGENESIS; COLONIC NEOPLASMS; COLONIC POLYPS; COLORECTAL CANCER GENES

Mesh:

Substances:

Year:  2015        PMID: 26475632     DOI: 10.1136/gutjnl-2015-310456

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  54 in total

1.  Associations between molecular characteristics of colorectal serrated polyps and subsequent advanced colorectal neoplasia.

Authors:  Xinwei Hua; Polly A Newcomb; Jessica Chubak; Rachel C Malen; Rebecca Ziebell; Aruna Kamineni; Lee-Ching Zhu; Melissa P Upton; Michelle A Wurscher; Sushma S Thomas; Hana Newman; Sheetal Hardikar; Andrea N Burnett-Hartman
Journal:  Cancer Causes Control       Date:  2020-05-01       Impact factor: 2.506

Review 2.  Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells.

Authors:  Ugo Testa; Elvira Pelosi; Germana Castelli
Journal:  Med Sci (Basel)       Date:  2018-04-13

3.  Low Sensitivity of Fecal Immunochemical Tests (FIT) for Detection of Sessile Serrated Adenomas/Polyps Confirmed Over Clinical Setting, Geography, and FIT System.

Authors:  Craig Mowat; Jayne Digby; Judith A Strachan; Robert J C Steele; Callum G Fraser
Journal:  Dig Dis Sci       Date:  2019-05-18       Impact factor: 3.199

4.  Mapping clinicopathological entities within colorectal mucinous adenocarcinomas: a hierarchical clustering approach.

Authors:  Charly Liddell; Laure Droy-Dupré; Sylvie Métairie; Fabrice Airaud; Christelle Volteau; Stéphane Bezieau; Christian L Laboisse; Jean-François Mosnier
Journal:  Mod Pathol       Date:  2017-04-21       Impact factor: 7.842

5.  The role of APC in WNT pathway activation in serrated neoplasia.

Authors:  Jennifer Borowsky; Troy Dumenil; Mark Bettington; Sally-Ann Pearson; Catherine Bond; Lochlan Fennell; Cheng Liu; Diane McKeone; Christophe Rosty; Ian Brown; Neal Walker; Barbara Leggett; Vicki Whitehall
Journal:  Mod Pathol       Date:  2017-11-17       Impact factor: 7.842

6.  Clinicopathologic and outcome study of sessile serrated adenomas/polyps with serrated versus intestinal dysplasia.

Authors:  Odise Cenaj; Joanna Gibson; Robert D Odze
Journal:  Mod Pathol       Date:  2017-12-22       Impact factor: 7.842

7.  Predictive Chromoendoscopy of Serrated Polyps: Is the Pendulum Swinging Toward the Pit Pattern?

Authors:  Joseph C Anderson; Amitabh Srivastava
Journal:  Dig Dis Sci       Date:  2018-07       Impact factor: 3.199

Review 8.  Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine.

Authors:  Shuji Ogino; Jonathan A Nowak; Tsuyoshi Hamada; Amanda I Phipps; Ulrike Peters; Danny A Milner; Edward L Giovannucci; Reiko Nishihara; Marios Giannakis; Wendy S Garrett; Mingyang Song
Journal:  Gut       Date:  2018-02-06       Impact factor: 23.059

9.  Clinicopathological and molecular correlations in traditional serrated adenoma.

Authors:  Shigeki Sekine; Satoshi Yamashita; Masayoshi Yamada; Taiki Hashimoto; Reiko Ogawa; Hiroshi Yoshida; Hirokazu Taniguchi; Motohiro Kojima; Toshikazu Ushijima; Yutaka Saito
Journal:  J Gastroenterol       Date:  2020-02-12       Impact factor: 7.527

Review 10.  The Serrated Polyp Pathway: Is It Time to Alter Surveillance Guidelines?

Authors:  Brendon O'Connell; Nazar Hafiz; Seth Crockett
Journal:  Curr Gastroenterol Rep       Date:  2017-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.